Back to results
US 2012/0058910 A1Published application
METHOD FOR DIAGNOSING ACUTE LYMPHOMIC LEUKEMIA (ALL) USING MIR-125b
AssigneeThe Ohio State University Research Foundation
InventorCarlo M. Croce
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins.
Claims4
A method of diagnosing whether a subject has, or is at risk for developing, acute lymphomic leukemia (ALL), comprising:
- measuring the level of at least miR-125b gene product in a test sample from the subject,
- wherein a decrease in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, ALL.
A method of determining the prognosis of a subject with ALL cancer, comprising:
- measuring the level of at least miR-125b gene product in a test sample from the subject,
- wherein the miR gene product is associated with an adverse prognosis in ALL;
- and
- wherein a decrease in the level of the at least one miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of an adverse prognosis.
1 more element
A method of diagnosing whether a subject has, or is at risk for developing, ALL, comprising:
- (1) reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;
- (2) hybridizing the target oligodeoxynucleotides to a microarray comprising at least one miR-125b miRNA-specific probe oligonucleotide to provide a hybridization profile for the test sample;
- and
- (3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample,
- wherein a down-regulated signal of at least one miRNA, relative to the signal generated from the control sample, is indicative of the subject either having, or being at risk for developing, ALL.
2 more elements
A method of diagnosing whether a subject has, or is at risk for developing, ALL with an adverse prognosis in a subject, comprising:
- (1) reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;
- (2) hybridizing the target oligodeoxynucleotides to a microarray comprising at least one miR-125b miRNA-specific probe oligonucleotide to provide a hybridization profile for the test sample;
- and
- (3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample,
- wherein a down-regulated signal of at least one miRNA, relative to the signal generated from the control sample, is indicative of the subject either having, or being at risk for developing, ALL.
2 more elements
Dependencies are inferred from the claim text.